Clinical Trial Update: Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing a PD-1 antibody in combination with chemoradiotherapy for high-risk recurrent nasopharyngeal carcinoma; the trial is currently active an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING